Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Post-Marketing Assessment of Immunogenicity and Safety of Unituxin™ in High-Risk Neuroblastoma Patients

Complete title: SC-4011, A Post-Marketing Study to Further Assess the Immunogenicity and Safety of UnituxinTM in High-Risk Neuroblastoma Patients

Research Study Number SC-4011
 
Principal Investigator Julie Park, MD
 
Phase IV

Research Study Description

The purpose of this study is to assess the incidence of human anti-chimeric antibody (HACA) in high-risk neuroblastoma patients treated with Unituxin combination therapy.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number SC-4011
 
Contact Julie Park, MD
 
Telephone 206/667-1212
 
E-mail
 

Keywords: Neuroblastoma; Neuroectodermal Tumors, Primitive (PNET); Solid Tumors; Neoplasms, Germ Cell and Embryonal; Neuroectodermal Tumors; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Neoplasms, Neuroepithelial

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials